

Rheumatology

Eddie Needham, MD Program Director and Academic Chairman AdventHealth Winter Park Family Medicine Residency Program Professor, Loma Linda University School of Medicine Eddie.Needham.MD@AdventHealth



Lecture Modules

- Systemic Lupus Erythematosus
- Progressive Systemic Sclerosis/scleroderma
- Dermatomyositis/Polymyositis
- Proximal myopathies
- RA vs OA



General Comments re: CTD (Connective Tissue Diseases)

- Pattern recognition is invaluable in assessing for potential CTDs
- Women are affected much more frequently than men for almost all CTDs
- Most CTD patients should be managed with the help of a rheumatologist when prescribing immunomodulators or biologic agents



















Patient Case

- 37 yo female presents with progressive shortness of breath.
- Has given birth to 5 healthy children previously without difficulty.
- Other complaints include:
 - Knee and elbow pain
 - Patchy hair loss



Patient Case

- Labs of note:
 - ANA (+) at 1:320
 - Platelet count of 96
 - WBC 3.5
 - Lymphocyte count of 1200
- Exam notable for bilateral pleural effusions



37 yo female with dyspnea, arthralgias, (+) ANA, mild pancytopenia, and pleural effusion. What is the most likely diagnosis?

- A. Rheumatoid arthritis
- B. Systemic lupus erythematosus
- C. Wegener's granulomatosis
- D. Sarcoidosis



Systemic Lupus Erythematosus (SLE)

- SLE is a systemic inflammatory autoimmune disease with protean manifestations.
- Female: male incidence of 9:1
- Typically affects women of child bearing years
- US prevalence of 0.1% (1 per 1000)
- More prevalent and severe among blacks and Hispanics



SLE

- Estimated survival rates of 96% at 5 years, 93% at 10 years, and 78% at 15-20 years.
 - Previously, 50% at 5 years in the 1950's
- Major causes of mortality is premature coronary artery disease with a three fold increase over general population.
- Increased risk of osteoporosis
 - From disease and drugs (steroids)
 - 3 months of prednisone 5mg/day or more \rightarrow DEXA



SLE

- The diagnosis is clinical
- (+) ANA not always helpful
- Must have 4 of 11 diagnostic criteria
- Lab tests cannot substitute for pattern recognition in the history and physical by the physician!

SLE Diagnostic Criteria



- Mucocutaneous signs 4 of them
- Brain seizures, psychosis
- Lab (+) ANA
- Lab other immune criteria
- Arthritis nonerosive (vs Rheumatoid Arthritis)
- Serositis
- Hematologic disturbances
- Renal disease



Lab

- (+) ANA
 - 90% of patients with SLE have a (+) ANA
- Negative at < 1:40 serum dilutions
- Indeterminate at 1:40 1:160
- Clearly positive at > 1:320



Lab

- False (+) RPR
- Prolonged PTT (Lupus anticoagulant)
- (+) Anti-Smith antibodies
- (+) Anti-double stranded DNA antibodies
- (+) Anticardiolipin antibodies
- (+) Lupus erythematosus cell prep



Renal involvement

- Proteinuria > 0.5 grams/day
- > 3+ protein on dipstick
- Cellular casts indicative of renal disease
 - RBC casts suggest glomerulonephritis
 - Tubular casts suggest inflammation of the tubules



Clinical Manifestations of SLE

American College of Rheumatology Slide Set













Normal eye grounds

Bulls-eye maculopathy from hydroxychloroquine

RATES FAMILY MEDICINE SOCIETY شعبة الإمارات لطب الأس

© ACR



SLE Treatment

- NSAIDs
 - Can be used early in SLE treatment
 - Effective for arthralgias and serositis
 - Avoid with lupus nephritis and renal insufficiency
 - Avoid Cox-2 inhibitors in patients with an increased risk of CVD

SLE treatment



- Steroids
 - High dose steroids can be used to manage severe disease episodes
 - May serve as bridge therapy until slow-acting drugs become effective
 - Low dose (5mg daily) can be used in the treatment of mild SLE
 - Topical steroids for localized skin manifestations
 - Intra-articular steroids for joint disease
 - Rule out septic arthritis first



SLE treatment

- Hydroxychloroquine
 - All SLE pts should be on hydroxychloroquine unless not tolerated
 - Requires 6-12 weeks to show benefit.
 - Can be combined with NSAIDs for mild disease
 - Cutaneous manifestations and arthralgias

The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324(3):150-154

emirates family medicine society شعبة الإمارات لطب الأسرة TORVORUSS

SLE treatment - Other immunomodulatory drugs

- Methotrexate some benefit
- Mycophenolate mofetil (Cellcept)
- Cyclophosphamide
 - Historically used for lupus nephritis
- Biologics belimumab and rituxamb (off label)

Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus Ann Rheum Dis. 2019;78(6):736. Epub 2019 Mar 29.



Which of the following is not a cause of an elevated ESR?

- A. Acute gout flare
- B. SLE/Lupus
- C. Polymyalgia rheumatic
- D. Fibromyalgia



Etiologies of elevated ESR > 100mm/hour

- Acute gout
- Polymyalgia rheumatica/temporal arteritis
- Rheumatoid arthritis
- SLE/active CTDs
- Infections:
 - Osteomyelitis, Subacute bacterial endocarditits, deep tissue abscess
- Cancer:
 - Carcinoma, leukemia, lymphoma, multiple myeloma

Zacharski LR, Kyle RA. Significance of extreme elevation of erythrocyte sedimentation rate. JAMA. 1967;202(4):264-266.

A 47 yo female presents with progressive dyspnea and edema. Exam notable with tight skin over hands bilateral (picture below) and face/cheeks. Labs show ANA (+) with nucleolar pattern. PFTs show restrictive lung disease. Which of the following is the most likely cause?

- A. Scleroderma
- B. Dermatomyositis
- C. Rheumatoid arthritis
- D. Raynaud's phenomenon





Scleroderma (Progressive Systemic Sclerosis)



Scleroderma

- A chronic condition characterized by fibrosis of the skin and internal organs
- Raynaud's phenomenon is present in most patients at some stage of the disease
- Prevalence between 20-250 patients per 10⁶
- Women have a 5 fold increased risk
- Survival of 78% at 5 years, 55% at 10 years, 37% at 15 years, and 27% at 20 years
- 60% of patients die from pulmonary disease



Scleroderma

- Major criterion is symmetric sclerosis
 - Skin thickening
- Minor criteria
 - Sclerodactyly thickening/tightening of the fingers
 - Digital pitting or loss of finger tip pad substance
 - Bilateral basilar pulmonary fibrosis



CREST syndrome

- Calcinosis
- Raynaud's phenomenon
- Esophageal dysmotility
- Sclerodactyly
- Telangiectasia


Lab testing

- Most patients have a (+) ANA
- Nucleolar pattern is present in 30%
- Anti-topoisomerase-1 Ab (Scl-70) are associated with diffuse scleroderma
 - Present in 40% of patients
- Anti-centromere Ab are present in 75% of patients with limited scleroderma and CREST



Routine monitoring every 6 months

- Complete blood count
- Creatinine level
- ESR
- Urinalysis
- ECG
- Echocardiogram (for right heart failure/pulmonary HTN)
- PFTs: +/- DLCO to check for fibrosis



Clinical manifestations of Scleroderma















Mauskapf Mouse Face



RATES FAMILY MEDICINE SOCIETY شعبة الإمارات لطب الأس





RATES FAMILY MEDICINE SOCIETY شعبة الإمارات لطب الأس















Scleroderma Treatment

- Arthralgias can be treated with:
 - NSAIDs, hydroxychloroquine, MTX, azathioprine, or mycophenolate
- Inflammatory episodes: steroids
- Any patient with scleroderma and HTN should be on an ACEI to preserve renal function
- Esophageal disease/reflux: PPI
- Pulmonary Disease: Cyclophosphamide



Scleroderma Treatment

- Raynaud's phenomenon:
 - Calcium channel blockers: extended-release
 - Nifedipine or amlodipine
 - IV iloprost (prostacyclin analogue vasodilator)
 - Sildenafil (phosphodiesterase inhibitor leading to vasodilation)



Rheumatology #2



Patient Case

- 47 yo male with three-year history of progressive weakness.
- He has trouble brushing his hair or reaching over his head.
- MRI brain and spine normal 3 years ago
- 6' 5" male sitting in NAD
- Can't get out of a chair without leaning far forward; cannot raise arms past 90 degrees
- He is on no meds at present



47 yo male with shoulder girdle weakness and normal brain MRI. Blood pressures are 130/70. No recent viral symptoms. Most likely diagnosis?

- A. Poliomyelitis
- B. Polymyositis
- C. COVID myopathy
- D. Cushing's syndrome



Polymyositis



Patient Case

- Patient with similar complaints with:
 - Erythematous plaques on the dorsal MCPs and PIPs of both hands
 - Erythematous patches and plaques on the upper eyelid



Dermatomyositis Gottron's papules and

Heliotrope rash



Findings in both DM and PM

- Elevations in muscle enzymes
 - CPK, muscle aldolase, LDH, AST, ALT
- Symmetric proximal muscle weakness
- Characteristic EMG findings
- (+) anti-Jo-1 antibodies
- Muscle biopsy demonstrating active inflammation
- Additionally in DM
 - Heliotrope rash and Gottron's papules

DDx for proximal muscle weakness



- DM/PM
- Polymyalgia rheumatica
- Temporal arteritis
- Endocrinopathy
 - Thyroid
 - Cushing's disease
 - Parathyroid
- Infections
 - Toxoplasma, trichinosis
 - Viral

- Glucocorticoid myopathy
- Statin myopathy
- Neurologic disorders
 - Myasthenia Gravis
 - Eaton-Lambert
 - Amyotrophic lateral sclerosis
- Muscular dystrophies
- Myopathies
- Electrolyte disturbances





RATES FAMILY MEDICINE SOCIETY شعبة الإمار ات لطب الأس



RATES FAMILY MEDICINE SOCIETY شعبة الإمارات لطب الأس



Dermatomyositis

- Both DM and PM increase the risk of cancer, DM>PM
 - 3 fold increase in RR in DM; 2 fold increase with PM
 - 70% of cancers are peritoneal adenocarcinomas
- Recommend age appropriate cancer screening for patients (Colonoscopy pts > 50 yo, etc...)
- In higher risk patients, consider CT Chest, Abdomen, Pelvis

Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326:363.



DM/PM treatment

- Initial high dose steroids to placate the inflammatory myopathy: 60-80mg daily
 - Wean down over ~ 1 year
- Steroid sparing agents:
 - Azathioprine
 - Methotrexate
 - Hydroxychloroquine

A 37 yo woman presents with painful swollen joints in her hands. No recent URI symptoms. No F/C, (+) general fatigue, weight stable. What is the most likely diagnosis?

- A. Rheumatoid arthritis
- B. Dermatomyositis
- C. Sjogren's syndrome
- D. Gout



Rheumatoid Arthritis - Epidemiology



- RA is the most common autoimmune **inflammatory** arthritis
 - Gout is inflammatory, but not autoimmune
 - OA is arthritis but not actively inflammatory
- Inflammation: tumor/swelling, dolor/pain, calor/warmth, rubor/erythema
- Lifetime prevalence of 0.25 1%
- Most common in women 30-50 years old, smokers, and patients with a (+) family history of RA
- Most commonly affects the proximal joints of the hands and feet
 - MCP, MTP, and PIP
 - Does not commonly affect DIP or lumbar spine

RA differential diagnosis



- Osteoarthritis
 - Not inflammatory. Lab tests either negative or false (+)
 - ANA (+) in 10% of population
- Gout
 - Usually monoarticular; Podagra/inflammation at first MTP in 50% gout patients
 - RA specific tests, RA, ACPA, usually negative
 - CRP and ESR can be quite elevated in acute gout
- CTD: SLE/Lupus, Sjogren's syndrome, Dermato-/Polymyositis
 - Diagnostic clues
 - Labs tests: ANA with pattern
- Fibromyalgia
 - No signs of active inflammation
 - Diagnostic tests negative
OA vs RA

Osteoarthritis

- Large joints: knees, hips, spine, DIPs
- DIPs Heberden's nodes
- Carpometacarpal joint of the thumb is commonly involved.
- Swelling of the joints is hard and bony in OA.
- Stiffness after use evening
- Xray joint space narrowing, osteophytes

Rheumatoid Arthritis

- Small joints: MCP, MTP, PIP
- Swan neck and boutonniere deformities
- Soft, warm, boggy, and tender joints
- Signs of inflammation: tumor, dolor, calor, rubor
- Stiffness worse after rest morning stiffness > 30 minutes
- Xray joint space destruction, erosions, soft tissue edema



Tests specific for Rheumatoid Arthritis

- Rheumatoid factor (RF)
 - IgM antibody
 - Can be elevated in other conditions than RA
 - 5-10% of general population has a (+) RF
- Anticyclic citrullinated peptide antibodies (ACPA)
- RF and ACPA are both negative in 50% of patients at initial presentation.
- They are both (+) in 80% pts long term.
- Of note, 30% of RA pts have a (+) ANA



Diagnostic criteria : Need ≥6 points to diagnose Rheumatoid Arthritis

• Joint involvement

One large joint	0
 Two to 10 large joints 	1
 One to three small joints 	2
 Four to 10 small joints 	3
 >10 joints (at least one small) 	5
 Serology 	
 Negative RF and negative ACPA 	0
 Low (+) RF or low (+) ACPA 	2

High (+) RF or high (+) ACPA

RF = Rheumatoid factor; ACPA = anti(cyclic)citrullinated protein antibodies

Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.

3



Diagnostic criteria : Need ≥6 points to diagnose Rheumatoid Arthritis

- Acute Phase Reactants
 - Normal CRP and normal ESR
 - Abnormal CRP or abnormal ESR
- Duration of symptoms
 - < 6 weeks 0
 - ≥ 6 weeks

1

N

• Total all points for final score

CRP = C-reactive protein; ESR = erythrocyte sedimentation rate

Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:2569.



FILTER RESULTS BY

Rheumatoid Arthritis Rheumatologic Rheuma

ACR/EULAR Criteria for Rheumatoid 🖈 Arthritis

RA diagnosis.

Age-Adjusted ESR/CRP for RA Adjusted ESR/CRP calculation.	*
CDAI for Rheumatoid Arthritis RA Severity, clinical data only.	*
DAS28-CRP for Rheumatoid Arthritis RA severity, specifically based on CRP.	*
DAS28-ESR for Rheumatoid Arthritis RA severity, specifically based on ESR.	*

long Critaria for APE

📶 Verizon 🗢		2:27	PM	🕈 68% 🔳
<	ACR/E	ULAR Criter	ia for Rheun	nato 🚖
CAL	CULATOR	NEXT STEPS	EVIDENCE	CREATOR
	citru	llinated protein	antibody	

2 Low-positive rheumatoid factor or low-positive anti-citrullinated protein antibody

³ High-positive rheumatoid factor or highpositive anti-citrullinated protein antibody

Acute-phase reactants (need at least one acute-phase reactant test result to use these criteria) According to lab

0 Normal CRP and normal ESR



Abnormal CRP or abnormal ESR

Duration of symptoms

Duration = patient self-report of the duration of synovitis signs/symptoms (e.g. pain, swelling, tenderness) in joints clinically involved at the time of assessment, regardless of treatment status

~



Definite RA 6 points

II Verizon 🗢		2:27	PM	4 68% 🔳	
< A	ACR/EULAR Criteria for Rheumato ★		Y MEDICINE SOCIETY شعبة الإمار ات		
CALCUL	TOR	NEXT STEPS	EVIDENCE	CREATOR	
	14				

.

Diagnoses rheumatoid arthritis (RA) in patients with undifferentiated inflammatory synovitis.

INSTRUCTIONS

Use in patients who have at least one swollen joint and no better explanation for synovitis.

When to Use 🌱

Why Use Y

Joint involvement

Any swollen/tender joint on exam, excluding <u>DIP</u> joints and 1st <u>MCP/MTP</u> joints; select option that assigns the most possible points; see <u>Evidence</u> for details

0 1 large joint

1 2-10 large joints

1-3 small joints (with or without involvement of large joints)

3 4-10 small joints (with or without involvement of large joints)













IRATES FAMILY MEDICINE SOCIETY شعبة الإمارات لطب الأسر

Lateral/fibular deviation can also happen in the feet











Progressive joint erosion

IILY MEDICINE SOCIETY شعبة الإمار ات لم



Hip joint destruction: moderate





Hip joint destruction: severe



EMIRATES FAMILY MEDICINE SOCIETY شعبة الإمارات لطب الأسرة





Treatment for RA

- Pretreatment screenings:
 - CBC, CMP (Cr, AST, ALT), others as indicated
 - Assessment of comorbidities
 - Immunizations
 - Hep B/C
 - Tuberculosis status
 - CXR
- Vaccinations



Which of the following DMARDs is first choice for a newly diagnosed RA pt?

A. Hydroxychloroquine

- B. Sulfasalazine
- C. Methotrexate
- D. Any of the biologic agents



Practice Recommendations

- 1. SLE malar rash, kidneys, joints, (+) ANA/labs
- 2. Consider hydroxychloroquine in all patients with SLE
- 3. RA small joints, (+) RF/ACPA/ESR/CRP
- 4. Select methotrexate (MTX) as the first line DMARD for most RA patients.

Thank you for your attention Eddie.Needham.MD@AdventHealth.com